Page 133 - Biomarkers for risk stratification and guidance in heart failure

Chapter 6
132
Table 1. Baseline characteristics of the overall population and divided by change in NT-proBNP and eGFR.
Patient characteristics Baseline
Overall
Decrease NT-proBNP Increase eGFR
Increase NT-proBNP
Age, yrs
Female
BMI
Hypertension
Diabetes Mellitus Hypercholesterolemia Stroke or TIA
Peripheral Artery Disease COPD
72.4 (12.1) 115 (42.4) 24.8 (4.6 ) 137 (50.6) 74 (27.3) 66 (24.4) 46 (17.0) 44 (16.2) 45 (16.6) 90 (33.2) 157 (57.9) 109 (40.2) 30 (11.1) 45 (16.6) 64 (23.6) 27 (10.0) 20 (7.4) 42 (15.5) 122 (49.8) 99 (36.5) 116 (43.0)
271 71.2 (13.3) 271 30 (54.5) 212 24.1 (5.2) 271 25 (45.5) 271 10 (18.2) 271 10 (18.2) 271 10 (18.2) 271 9 (16.4) 271 8 (14.5) 271 16 (29.1) 271 27 (49.1) 271 15 (27.3) 271 3 (5.5) 271 5 (9.1) 271 8 (14.5) 271 6 (10.9) 271 1 (1.8) 271 7 (12.7) 245 21 (42.9) 271 17 (30.9) 270 19 (34.5)
55 71.8 (11.7) 55 24 (34.3) 42 24.8 (4.4) 55 32 (45.7) 55 18 (25.7) 55 15 (21.4) 55 11 (15.7) 55 11 (15.7) 55 12 (17.1) 55 19 (27.1) 55 35 (50.0) 55 22 (31.4) 55 4 (5.7)
70 72.1 (10.3) 69 70 28 (40.6) 69 56 25.3 (4.3) 52 70 41 (59.4) 69 70 25 (36.2) 69 70 20 (29.0) 69 70 10 (14.5) 69 70 11 (15.9) 69 70 12 (17.4) 69 70 24 (34.8) 69 70 46 (66.7) 69 70 36 (52.2)**‡ 69 70 8 (11.6) 69 70 14 (20.3) 69 70 19 (27.5) 69 70 5 (7.2) 69 70 9 (13.0) **‡ 69 70 13 (18.8) 69 65 30 (49.2) 61 70 33 (47.8)‡ 69 70 34 (50.0) 68
74.2 (13.2) 77 33 (42.9) 77 24.9 (4.7) 62 39 (50.6) 77 21 (27.3) 77 21 (27.3) 77 15 (19.5) 77 13 (16.9) 77 13 (16.9) 77 31 (40.3) 77 49 (63.6) 77 36 (46.8)† 77 15 (19.5)†§ 77 16 (20.8) 77 25 (32.5)†§ 77 12 (15.6) 77 8 (10.4) 77 17 (22.1) 77 35 (50.0) 70 31 (40.3) 77 37 (48.1) 77
0.473 0.152 0.649 0.336 0.160 0.464 0.854 1.000 0.975 0.342 0.081 0.009 0.023 0.248 0.045 0.188 0.028 0.065 0.630 0.036 0.194
Atrial fibrillation
Coronary artery disease Myocardial infarction
PCI
CABG
PCI or CABG
Pacemaker
ICD
Pacemaker or ICD
Mitral regurgitation ≥ II Previous episode of HF Ischemic cause of HF Discharge
NYHA functional class ≥ III Mean Arterial Pressure, mmHg Heart rate, beats/minute
QRS duration, msec
LVEF
Hemoglobin, mmol/l
Sodium, mmol/l
55 10 (14.3) 55 12 (17.1) 55 4 (5.7) 55 2 (2.9) 55 5 (7.1) 49 36 (55.4) 55 18 (25.7) 55 26 (37.1)
(n=271)
n (n= 55)
Decrease eGFR n (n=70)
Increase eGFR
n (n=69) n
Decrease eGFR
(n=77) n
P overall
57 (21.0) 85.0 (12.8) 77.2 (15.8) 110 (94-138) 35.8 (14.7) 8.4 (1.2) 139.0 (3.5)
271 11 (20.0) 257 88.1 (12.7) 256 79.3 (18.1) 223 110 (93-127) 210 39.0 (15.5) 186 8.6 (1.3)
55 8 (11.4)
52 85.8 (11.9) 51 76.0 (15.5) 45 104 (91-129) 40 34.4 (13.0) 39 8.3 (1.2)
55 139.6 (3.5)
70 17 (24.6) 69 68 82.7 (12.3) 62 67 78.2 (15.0) 63 57 110 (94-150) 59 57 35.4 (15.3) 55 45 8.6 (1.3) 49 70 138.4 (3.3) 69
21 (27.3) 77 84.0 (13.6) 75 76.0 (15.4) 75 117 (96-147) 62 35.3 (15.3) 58 8.3 (1.1) 53 138.9 (3.4) 77
0.100 0.118 0.591 0.229 0.490 0.354 0.256
271 138.9 (3.6)